临床试验放疗质量保证综述:价值、演变与经验
该综述基于PubMed 1988–2022年文献及ClinicalTrials.gov注册库,评估放疗临床试验中质量保证(RTQA)的实施趋势与影响因素。共识别130项包含RTQA的研究,其中96项发表分析结果;仅约1.15%注册试验实施RTQA、0.84%发表结果,但实施RTQA的试验随时间更全面。
要点
- RTQA对确保临床试验放疗质量至关重要,但实施和发表比例均很低。
- 1988–2022年间RTQA实施率无显著增加,但实施者的RTQA更趋全面。
- 前瞻性RTQA比例随时间上升,基准案例/模拟运行从33.3%升至100%。
核心结论
- 尽管RTQA对确保放疗质量至关重要,但实施RTQA的试验数量少,发表RTQA结果的更少。
- 随时间推移未发现RTQA实施显著增加,但实施RTQA的试验其RTQA变得更全面。
研究设计与样本
- 综述分析PubMed 1988–2022年发表并报告RTQA结果的临床试验,并检索ClinicalTrials.gov注册库以获取涉及放疗的临床试验实际数量。
主要发现
- 1988–2022年间共识别130项研究在方法中纳入RTQA,其中96项试验发表了定性或定量分析。
- 同期与ClinicalTrials.gov注册试验相比,实施RTQA的试验占1.15%,发表RTQA结果的占0.84%。
- 前瞻性RTQA比例随时间增加:BC/DR从1988–1999年的33.3%升至2016–2022年的100%;ICR从16.7%升至50%。
临床怎么用
- 临床试验应常规实施RTQA以确保放疗质量及结果可靠性,并考虑自动化及根据试验、放疗技术和参与中心经验进行定制。
局限性
- 原文未报告综述的检索策略细节、纳入排除标准及偏倚风险评估方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Deviations in radiotherapy quality can significantly affect clinical trial outcomes, including overall survival. Radiotherapy quality assurance (RTQA) is a systematic process by which a RT plan is analyzed with respect to the trial protocol. Therefore, RTQA is an essential step in clinical trials involving radiotherapy to ensure the reliability of the results. The objective of this review was to assess RTQA trends over time and parameters influencing the type of RTQA. MATERIALS AND METHODS: This is an overview of trials published in PubMed between 1988 and 2022 which performed and published their RTQA results. A search was also performed on the ClinicalTrials.gov database to find the actual number of clinical trials involving radiotherapy as treatment. RESULTS: Between 1988 and 2022, 130 studies were identified to include RTQA in their methods. Of these studies, 96 trials published qualitative or quantitative analyses. During the same period, compared to registered trials on the Clinicaltrials.gov database, 1.15% and 0.84% of trials performed and published RTQA respectively. Seventy-three trials (58%) performed a benchmark case (BC) or dummy run (DR), 93 (73.8%) an individual case review and 24 (18,9%) an end-to-end audit. A higher proportion of prospective RTQA was found over time (BC/DR: 33.3% during 1988-1999 vs 100% during 2016-2022; ICR: 16.7% in 1988-1999 vs 50% in 2016-2022). CONCLUSION: In spite of RTQA being critical to ensure RT quality, a small number of trials perform it, and even fewer publish RTQA results. No significant increase in the conduction of RTQA over time was found, despite ongoing progress and increasing complexity in RT techniques. However, of the trials performing RTQA, this become more comprehensive over time. As RTQA continues to evolve in scope, including both contouring and plan review, consideration should be given to automation and tailoring to the specific trial, RT techniques and experience of the participating centers.Abbreviations: AI, artificial intelligence; BC/DR, benchmark case / dummy run; EORTC, European Organization for. Research and Treatment of Cancer; GHG, Global Clinical Trials RTQA Harmonization Group; GI, gastro-intestinal; HNSCC, head and neck squamous cell carcinoma; ICR, individual case review; IMRT, intensity modulated radiation therapy; OAR, organ at risk; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses; RT, radiotherapy; RTQA, radiotherapy quality assurance; SBRT, stereotactic body radiotherapy; TROG, Trans-Tasman Radiation Oncology Group.
引用
- Quellenec GL, Perennec T, Ollivier L, et al. A review of clinical trial radiotherapy quality assurance: value, evolution and lessons. Clin Transl Radiat Oncol. 2026. PMID: 42100291. doi:10.1016/j.ctro.2026.101171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。